Article in Antimicrobial agents and chemotherapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
11 authors.
Agnès B JoussetCenter for Immunology of Viral, Auto-immune, Hematological and Bacterial Diseases (IMVA-HB/IDMIT/UMRS1184), Université Paris-Saclay, Inserm, CEA, Fontenay-aux-Roses & Le Kremlin-Bicêtre, France.ORCID 0000-0002-8223-2213
Delphine GirlichCenter for Immunology of Viral, Auto-immune, Hematological and Bacterial Diseases (IMVA-HB/IDMIT/UMRS1184), Université Paris-Saclay, Inserm, CEA, Fontenay-aux-Roses & Le Kremlin-Bicêtre, France.
Saoussen OueslatiCenter for Immunology of Viral, Auto-immune, Hematological and Bacterial Diseases (IMVA-HB/IDMIT/UMRS1184), Université Paris-Saclay, Inserm, CEA, Fontenay-aux-Roses & Le Kremlin-Bicêtre, France.
Aurélien BirerFrench Associated National Reference Center for Antibiotic Resistance, Le Kremlin-Bicêtre, France.
Anne DelavalService de Bactériologie, Groupe Hospitalier Intercommunal du Raincy-Montfermeil, Montfermeil, France.
Caroline GuyotService de Bactériologie, Groupe Hospitalier Intercommunal du Raincy-Montfermeil, Montfermeil, France.
Ines RezzougCenter for Immunology of Viral, Auto-immune, Hematological and Bacterial Diseases (IMVA-HB/IDMIT/UMRS1184), Université Paris-Saclay, Inserm, CEA, Fontenay-aux-Roses & Le Kremlin-Bicêtre, France.ORCID 0009-0006-9484-7932
Cécile EmeraudCenter for Immunology of Viral, Auto-immune, Hematological and Bacterial Diseases (IMVA-HB/IDMIT/UMRS1184), Université Paris-Saclay, Inserm, CEA, Fontenay-aux-Roses & Le Kremlin-Bicêtre, France.ORCID 0009-0006-3595-6434
Thierry NaasCenter for Immunology of Viral, Auto-immune, Hematological and Bacterial Diseases (IMVA-HB/IDMIT/UMRS1184), Université Paris-Saclay, Inserm, CEA, Fontenay-aux-Roses & Le Kremlin-Bicêtre, France.ORCID 0000-0001-9937-9572
Rémy A BonninCenter for Immunology of Viral, Auto-immune, Hematological and Bacterial Diseases (IMVA-HB/IDMIT/UMRS1184), Université Paris-Saclay, Inserm, CEA, Fontenay-aux-Roses & Le Kremlin-Bicêtre, France.
Laurent DortetCenter for Immunology of Viral, Auto-immune, Hematological and Bacterial Diseases (IMVA-HB/IDMIT/UMRS1184), Université Paris-Saclay, Inserm, CEA, Fontenay-aux-Roses & Le Kremlin-Bicêtre, France.ORCID 0000-0001-6596-7384
Funding
Agence Nationale de la Recherche ANR-23-IAHU-0004
6 · The paper itself
Abstract
Resistance to ceftazidime-avibactam (CAZ-AVI) is a growing problem. This study describes the selection of CMY-219, a CMY-42 variant (G156D), conferring resistance to CAZ-AVI in an OXA-484-producing
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.